Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Global Biodefense Market, by Product
1.4.2 Global Biodefense Market, by Geography
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.2 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
3.1 Recent Industry Wide Strategic Developments
3.1.1 Partnerships, Collaborations and Agreements
3.1.2 Approvals
3.1.3 Acquisition and Mergers
3.2 Top Winning Strategies
3.2.1 Key Leading Strategies: Percentage Distribution (2016-2020)
3.2.2 Key Strategic Move: (Partnerships, Collaborations, and Agreements : 2017, Jul – 2020, Jul) Leading Players
Chapter 4. Global Biodefense Market by Product
4.1 Global Anthrax Market by Region
4.1.1 Global Smallpox Market by Region
4.1.2 Global Botulism Market by Region
4.1.3 Global Radiation/nuclear Market by Region
4.1.4 Global Other Product Market by Region
Chapter 5. Global Biodefense Market by Region
5.1 North America Biodefense Market
5.1.1 North America Biodefense Market by Product
5.1.1.1 North America Anthrax Market by Country
5.1.1.2 North America Smallpox Market by Country
5.1.1.3 North America Botulism Market by Country
5.1.1.4 North America Radiation/nuclear Market by Country
5.1.1.5 North America Other Product Market by Country
5.1.2 North America Biodefense Market by Country
5.1.2.1 US Biodefense Market
5.1.2.1.1 US Biodefense Market by Product
5.1.2.2 Canada Biodefense Market
5.1.2.2.1 Canada Biodefense Market by Product
5.1.2.3 Mexico Biodefense Market
5.1.2.3.1 Mexico Biodefense Market by Product
5.1.2.4 Rest of North America Biodefense Market
5.1.2.4.1 Rest of North America Biodefense Market by Product
5.2 Europe Biodefense Market
5.2.1 Europe Biodefense Market by Product
5.2.1.1 Europe Anthrax Market by Country
5.2.1.2 Europe Smallpox Market by Country
5.2.1.3 Europe Botulism Market by Country
5.2.1.4 Europe Radiation/nuclear Market by Country
5.2.1.5 Europe Other Product Market by Country
5.2.2 Europe Biodefense Market by Country
5.2.2.1 Germany Biodefense Market
5.2.2.1.1 Germany Biodefense Market by Product
5.2.2.2 UK Biodefense Market
5.2.2.2.1 UK Biodefense Market by Product
5.2.2.3 France Biodefense Market
5.2.2.3.1 France Biodefense Market by Product
5.2.2.4 Russia Biodefense Market
5.2.2.4.1 Russia Biodefense Market by Product
5.2.2.5 Spain Biodefense Market
5.2.2.5.1 Spain Biodefense Market by Product
5.2.2.6 Italy Biodefense Market
5.2.2.6.1 Italy Biodefense Market by Product
5.2.2.7 Rest of Europe Biodefense Market
5.2.2.7.1 Rest of Europe Biodefense Market by Product
5.3 Asia Pacific Biodefense Market
5.3.1 Asia Pacific Biodefense Market by Product
5.3.1.1 Asia Pacific Anthrax Market by Country
5.3.1.2 Asia Pacific Smallpox Market by Country
5.3.1.3 Asia Pacific Botulism Market by Country
5.3.1.4 Asia Pacific Radiation/nuclear Market by Country
5.3.1.5 Asia Pacific Other Product Market by Country
5.3.2 Asia Pacific Biodefense Market by Country
5.3.2.1 China Biodefense Market
5.3.2.1.1 China Biodefense Market by Product
5.3.2.2 Japan Biodefense Market
5.3.2.2.1 Japan Biodefense Market by Product
5.3.2.3 India Biodefense Market
5.3.2.3.1 India Biodefense Market by Product
5.3.2.4 South Korea Biodefense Market
5.3.2.4.1 South Korea Biodefense Market by Product
5.3.2.5 Singapore Biodefense Market
5.3.2.5.1 Singapore Biodefense Market by Product
5.3.2.6 Malaysia Biodefense Market
5.3.2.6.1 Malaysia Biodefense Market by Product
5.3.2.7 Rest of Asia Pacific Biodefense Market
5.3.2.7.1 Rest of Asia Pacific Biodefense Market by Product
5.4 LAMEA Biodefense Market
5.4.1 LAMEA Biodefense Market by Product
5.4.1.1 LAMEA Anthrax Market by Country
5.4.1.2 LAMEA Smallpox Market by Country
5.4.1.3 LAMEA Botulism Market by Country
5.4.1.4 LAMEA Radiation/nuclear Market by Country
5.4.1.5 LAMEA Other Product Market by Country
5.4.2 LAMEA Biodefense Market by Country
5.4.2.1 Brazil Biodefense Market
5.4.2.1.1 Brazil Biodefense Market by Product
5.4.2.2 Argentina Biodefense Market
5.4.2.2.1 Argentina Biodefense Market by Product
5.4.2.3 UAE Biodefense Market
5.4.2.3.1 UAE Biodefense Market by Product
5.4.2.4 Saudi Arabia Biodefense Market
5.4.2.4.1 Saudi Arabia Biodefense Market by Product
5.4.2.5 South Africa Biodefense Market
5.4.2.5.1 South Africa Biodefense Market by Product
5.4.2.6 Nigeria Biodefense Market
5.4.2.6.1 Nigeria Biodefense Market by Product
5.4.2.7 Rest of LAMEA Biodefense Market
5.4.2.7.1 Rest of LAMEA Biodefense Market by Product
Chapter 6. Company Profiles
6.1 Xoma Corporation
6.1.1 Company Overview
6.1.2 Financial Analysis
6.1.3 Regional Analysis
6.1.4 Research & Development Expense
6.2 Altimmune, Inc.
6.2.1 Company Overview
6.2.2 Financial Analysis
6.2.3 Research & Development Expense
6.2.4 Recent strategies and developments:
6.2.4.1 Acquisition and Mergers:
6.2.4.2 Partnerships, Collaborations, and Agreements:
6.3 Emergent BioSolutions, Inc.
6.3.1 Company Overview
6.3.2 Financial Analysis
6.3.3 Research & Development Expense
6.3.4 Recent strategies and developments:
6.3.4.1 Acquisition and Mergers:
6.3.4.2 Partnerships, Collaborations, and Agreements:
6.4 Dynavax Technologies Corporation
6.4.1 Company Overview
6.4.2 Financial Analysis
6.4.3 Research & Development Expense
6.5 SIGA Technologies, Inc.
6.5.1 Company Overview
6.5.2 Financial Analysis
6.5.3 Research & Development Expense
6.5.4 Recent strategies and developments:
6.5.4.1 Partnerships, Collaborations, and Agreements:
6.5.4.2 Approvals:
6.6 Elusys Therapeutics, Inc.
6.6.1 Company Overview
6.6.2 Recent strategies and developments:
6.6.2.1 Approvals:
6.7 Ichor Holdings, Ltd.
6.7.1 Company Overview
6.7.2 Financial Analysis
6.7.3 Regional Analysis
6.7.4 Research & Development Expense
6.7.5 Recent strategies and developments:
6.7.5.1 Partnerships, Collaborations, and Agreements:
6.8 Cleveland BioLabs, Inc.
6.8.1 Company Overview
6.8.2 Financial Analysis
6.8.3 Research & Development Expense
6.8.4 Recent strategies and developments:
6.8.4.1 Partnerships, Collaborations, and Agreements:
6.9 Bavarian Nordic A/S
6.9.1 Company Overview
6.9.2 Financial Analysis
6.9.3 Regional Analysis
6.9.4 Research & Development Expense
6.9.5 Recent strategies and developments:
6.9.5.1 Partnerships, Collaborations, and Agreements:
6.9.5.2 Approvals:
6.10. Alnylam Pharmaceuticals, Inc.
6.10.1 Company Overview
6.10.2 Financial Analysis
6.10.3 Research & Development Expense
Unique Offerings 